BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?
Corresponding Author
Yasuhiro Ito
- [email protected]
- +81-78-371-3721 | Fax: +81-78-371-3645
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Tel.: +81-78-371-3721, Fax: +81-78-371-3645, [email protected]Search for more papers by this authorHiroshi Yoshida
Department of Research, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorMinoru Kihara
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorKaoru Kobayashi
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorAkihiro Miya
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorAkira Miyauchi
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorCorresponding Author
Yasuhiro Ito
- [email protected]
- +81-78-371-3721 | Fax: +81-78-371-3645
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Tel.: +81-78-371-3721, Fax: +81-78-371-3645, [email protected]Search for more papers by this authorHiroshi Yoshida
Department of Research, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorMinoru Kihara
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorKaoru Kobayashi
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorAkihiro Miya
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorAkira Miyauchi
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan
Search for more papers by this authorAbstract
Background
The BRAFV600E mutation has been adopted as a prognostic factor in papillary thyroid carcinoma (PTC). However, it remains unclear whether routine BRAF mutation analysis is useful in establishing a prognosis for PTC patients. In the present study we investigated BRAF mutation analysis in a large number of PTC patients with long-term follow-up.
Patients and methods
We enrolled 766 patients from our hospital who underwent initial surgery for PTC without distant metastasis at diagnosis between 1996 and 2001, and whose BRAF mutation of primary lesions could be analyzed. The average age and follow-up period were 51 years and 130 months, respectively.
Results
To date, 77 (10 %) and 37 (5 %) patients have developed lymph node and distant recurrence, respectively, and 10 (1 %) have died of PTC. The BRAF mutation was positive in 281 patients (37 %), and it had no prognostic impact on lymph node recurrence-free (LNRFS) (p = 0.700), distant recurrence-free (DRFS) (p = 0.696), and cause-specific (CSS) (p = 0.125) survival in our entire series. However, CSS of BRAF mutation-positive high-risk patients based on AMES (p = 0.030), MACIS (score >6) (p = 0.017), the UICC stage (IVa) (p = 0.021), CIH classification (Sugitani et al. Surgery 135:139–148, 2004) (p = 0.015), and our own classification system (Ito et al. World J Surg 34:2570–2580, 2010) (p = 0.010) were significantly poorer than CSS of mutation-negative high-risk patients. The BFAF mutation did not affect CSS of non-high-risk patients, although the incidence of the BRAF mutation did not significantly differ between high-risk and non-high-risk groups based on these classification systems. The BRAF mutation was not related to LNRFS and DRFS in the subsets of high-risk and non-high-risk patients.
Conclusions
BRAF mutation analysis is useful in estimating the CSS of high-risk PTC patients based on the representative classification systems. It was not related to the prognosis in non-high-risk patients, at least those living in Japan.
References
- 1ItoY, TomodaC, UrunoT et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg (2006) 30: 780–7861641101310.1007/s00268-005-0270-z
- 2ItoY, TomodaC, UrunoT et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg (2005) 29: 917–9201595192710.1007/s00268-005-7789-x
- 3ItoY, KudoT, KobayashiK et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with 10-year follow-up. World J Surg (2012) 36: 1274–12782227099010.1007/s00268-012-1423-5
- 4MaraisR, MarshallCJ PJ Parker, T Pawson Control of the ERK MAP kinase cascade by Ras and Raf. Cell signaling (1996) Cold Spring HarborCold Spring Harbor Laboratory Press 101–125
- 5MercerKE, PritchardCA Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta (2003) 1653: 25–4012781369
- 6NambaH, NakashimaM, HayashiT et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab (2003) 88: 4393–43971297031510.1210/jc.2003-030305
- 7KimTY, KimWB, RheeYS et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (2006) 65: 364–36810.1111/j.1365-2265.2006.02605.x
- 8AdemiranAJ, ZhuZ, GandhiM et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 30: 216–22210.1097/01.pas.0000176432.73455.1b
- 9FugazzolaL, PeuxedduE, AveniaN et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer (2006) 13: 455–4641672857310.1677/erc.1.01086
- 10KebebewE, WengJ, BauerJ et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 246: 466–4711771745010.1097/SLA.0b013e318148563d
- 11LupiC, GlanniniR, UgoliniC et al. Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 92: 4085–40901778535510.1210/jc.2007-1179
- 12NikiforovaMN, KimuraET, GandhiM et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 88: 5399–54041460278010.1210/jc.2003-030838
- 13Riesco-EizaguirreG, Gutierrez-MartinezP, Garcia-CabezasMA et al. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane. Endocr Relat Cancer (2006) 13: 257–2691660129310.1677/erc.1.01119
- 14XingM, WestraWH, TufanoRP et al. BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 90: 6373–63791617471710.1210/jc.2005-0987
- 15FrascaF, NuceraC, PelligretiG et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer (2008) 15: 191–2051831028710.1677/ERC-07-0212
- 16ElliseiR, UgoliniC, ViolaD et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: 15-year median follow-up study. J Clin Endocrinol Metab (2008) 93: 3943–394910.1210/jc.2008-0607
- 17KwakJY, EkimEK, ChungWY et al. Association of BTAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology (2009) 253: 854–8601971000110.1148/radiol.2533090471
- 18O’NeillCJ, BullockM, ChouA et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery (2010) 148: 1139–11452113454410.1016/j.surg.2010.09.005
- 19KimTH, ParkYJ, LimJA et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer (2012) 118: 1764–17732188218410.1002/cncr.26500
- 20TufanoRP, TelxeiraFB, BishopJ et al. BRAF mutation in papillary tyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (2012) 91: 274–2862293278610.1097/MD.0b013e31826a9c71
- 21LeeCLK, SchneiderEB, ZeigerMA BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 97: 4559–45702305554610.1210/jc.2012-2104
- 22ElliseiR, ViolaD, TorregrossaL et al. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results form a large cohort study. J Clin Endocrinol Metab (2012) 97: 4390–439810.1210/jc.2012-1775
- 23GuerraA, FugazzolaL, MarottaV et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab (2012) 97: 2333–23402250870610.1210/jc.2011-3106
- 24Ricarte-FilhoJ, GanlyI, RiveraM et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid (2012) 22: 575–5842247124210.1089/thy.2011.0431
- 25KimSJ, LeeKE, MyongJP et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 36: 310–3172219022210.1007/s00268-011-1383-1
- 26PrescottJD, SadowPM, HodinRA et al. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery (2012) 152: 984–9902315817210.1016/j.surg.2012.08.039
- 27AbrosimovA, SaenkoV, RogounovitchT et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer (2007) 120: 196–2001704402810.1002/ijc.22290
- 28FugazzolaL, MannavolaD, CirelloV et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (2004) 61: 239–24310.1111/j.1365-2265.2004.02089.x
- 29SapinoMR, PoscaD, RaggioliA et al. Detection of RET/PTC, TRK, and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (2007) 66: 678–68310.1111/j.1365-2265.2007.02800.x
- 30BrzezianskaE, Pastuszak-LewandoskaD, WojciechowskaK et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett (2007) 28: 351–35917693984
- 31KimTY, KimWB, SongJY et al. The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinoil (2005) 63: 588–59310.1111/j.1365-2265.2005.02389.x
- 32LiuRT, ChenYJ, ChouFF et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (2005) 63: 461–46610.1111/j.1365-2265.2005.02367.x
- 33StanojevicB, DzodicR, SaenkoV et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J (2011) 58: 381–3932149891610.1507/endocrj.K11E-054
- 34SancisiV, NicoliD, RagazziM et al. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcnomas. J Clin Endocrinol Metab (2012) 97: 1745–174910.1210/jc.2012-1526
- 35KurtB, YalcunS, AlagozE et al. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol (2012) 23: 135–1402276744610.1007/s12022-012-9218-7
- 36UlisseS, BaldiniE, SorrentiS et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol (2012) 77: 780–78610.1111/j.1365-2265.2012.04465.x
- 37AhnD, ParkJS, SohnJH et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nesus Larynx (2012) 39: 198–20310.1016/j.anl.2011.07.011
- 38NamJK, JungCK, SongBJ et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. Am J Surg (2012) 203: 436–4412180332910.1016/j.amjsurg.2011.02.013
- 39ItoY, YoshidaH, MaruoR et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J (2008) 56: 89–971884092410.1507/endocrj.K08E-208
- 40CadyB, RosaiR An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery (1988) 104: 947–9533194846
- 41HayID, BergstrahlEJ, GoellnerJR et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery (1993) 114: 1050–10588256208
- 42 LH Sobin, CH Wittekind UICC: TNM classification of malignant tumors (2011) 7New YorkWiley
- 43SugitaniI, KasaiN, FujimotoY et al. A novel classification system for patients with PTC: addition of the new variable of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery (2004) 135: 139–1481473984810.1016/S0039-6060(03)00384-2
- 44ItoY, IchiharaK, MasuokaH et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg (2010) 34: 2570–25802062572810.1007/s00268-010-0710-2
- 45DuranteC, PuxedduE, FerettiE et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab (2007) 92: 2840–29431748879610.1210/jc.2006-2707
- 46BarolloS, PennelliG, VianelloF et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F] fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol (2010) 163: 659–6632064730110.1530/EJE-10-0290
- 47GaoWL, WieLL, ChaoYG et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab (2012) 58: 919–92623163107
- 48GuerraA, SapioMR, MarottaV et al. The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 97: 517–5242217071410.1210/jc.2011-0618
- 49Brose MS, Nutting C, Jarzab B, et al (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer. The phase III DECISION trial. The 49th annual meeting of the American Society of Clinical Oncology (ASCO) Plenary session Abstract #4
